{"id":10935,"date":"2003-04-01T09:11:00","date_gmt":"2003-04-01T09:11:00","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10935"},"modified":"2014-05-28T16:03:40","modified_gmt":"2014-05-28T16:03:40","slug":"vaxgen-announces-disappointing-results-from-first-large-international-vaccine-trial","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10935","title":{"rendered":"Vaxgen announces disappointing results from first large international vaccine trial"},"content":{"rendered":"<p><strong>Bad news and good news on AIDSVAX phase III trials results<\/strong><\/p>\n<p><strong>Vaxgen Inc has announced the initial results from its three-year Phase III trials of AIDSVAX, a recombinant gp120 HIV vaccine.<\/strong><\/p>\n<p>The reduction of HIV infection within the vaccinated population as a whole was not statistically significant. However, there was a statistically significant reduction of HIV infection in vaccinated non-white, non-Hispanic volunteers. More importantly, protection in this subgroup appeared to correlate with a higher level of neutralising antibodies.<\/p>\n<p>Phillip Berman, VaxGen\u2019s senior vice president of Research and Development and inventor of the vaccine remarked that this is the first time they had specific numbers that suggested that a vaccine had prevented HIV infection in humans. He added that they were not sure why some subgroups of volunteers had a better immune response, but that the preliminary data indicated that a vaccine constructed with the virus\u2019 surface protein could elicit neutralizing antibodies that correlated with protection of infection.<\/p>\n<table border=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td colspan=\"4\"><strong>AIDSVAX B\/B Trial Statistics<\/strong><\/td>\n<\/tr>\n<tr>\n<td>No. of volunteers to complete 3 immunizations:<\/td>\n<td>5,009<\/td>\n<\/tr>\n<tr>\n<td>Placebo recipients:<\/td>\n<td>1,679<\/td>\n<\/tr>\n<tr>\n<td>AIDSVAX B\/B recipients:<\/td>\n<td>3,330<\/td>\n<\/tr>\n<tr>\n<td>White volunteers:<\/td>\n<td>4,185<\/td>\n<\/tr>\n<tr>\n<td>Hispanic volunteers:<\/td>\n<td>326<\/td>\n<\/tr>\n<tr>\n<td>Non-white volunteers (Black, Asian, Other):<\/td>\n<td>498<\/td>\n<\/tr>\n<tr>\n<td>Black volunteers:<\/td>\n<td>314<\/td>\n<\/tr>\n<tr>\n<td>Annual study infection rate<\/td>\n<td>2.7%<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\"><strong>Approximate Efficacy (after at least 3 primary doses)<\/strong><\/td>\n<\/tr>\n<tr>\n<td>All volunteers:<\/td>\n<td>3.8% (p-value = 0.76; confidence interval: -23% to 24%)<\/td>\n<\/tr>\n<tr>\n<td>Non-white volunteers:<\/td>\n<td>67% (p-value &lt; 0.01; confidence interval: 30% to 84%)<\/td>\n<\/tr>\n<tr>\n<td>Black volunteers:<\/td>\n<td>78% (p-value &lt; 0.02; confidence interval: 29% to 93%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Source:<br \/>\n<a href=\"http:\/\/www.aaas.org\/\">http:\/\/www.aaas.org\/<\/a><\/p>\n<p>Copyright (c) 2002 by the American Association for the Advancement of Science<strong><br \/>\n<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bad news and good news on AIDSVAX phase III trials results Vaxgen Inc has announced the initial results from its three-year Phase III trials of AIDSVAX, a recombinant gp120 HIV vaccine. The reduction of HIV infection within the vaccinated population &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[],"class_list":["post-10935","post","type-post","status-publish","format-standard","hentry","category-vaccines-and-microbicides"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10935"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10935\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}